Work

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study

Year: 2015

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2015.04.038

Authors: D. Scott McMeekin, Michael W. Sill, Joan L. Walker, Kathleen N. Moore, Steven E. Waggoner, Premal H. Thaker, Tina Rizack, James S. Hoffman, Paula M. Fracasso

Institutions: University of Oklahoma Health Sciences Center, NRG Oncology, Case Western Reserve University, Washington University in St. Louis, Women & Infants Hospital of Rhode Island, The Hospital of Central Connecticut, University of Virginia

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G1291646684, Washington University/ Siteman Cancer Center Lead Academic Site, G1950154987, G4054617085, NRG Oncology Network Group Operations Center, G434901823, G5996839100, G70736214, G8494369300, NRG Oncology - Statistical and Data Management Center

OpenAlex ID: W1884150837

FWCI: 0.971

Cites: 23

Cited by: 6

Related to: 10